-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is understood that the research and development of innovative drugs is difficult, and innovative traditional Chinese medicines are "difficult to produce" due to the particularity of their products
.
Statistics show that in 2020, the State Food and Drug Administration has approved 48 innovative drugs to be marketed.
There are only 3 traditional Chinese medicines.
They are Lianhuaqing Cough Tablets from Ling Pharmaceutical, Muscle and Bone Analgesic Gel from Kangyuan Pharmaceutical, and Wuhe Boao The total alkaloid tablets of mulberry branches
.
Although the number is not large, it has been a year in which more new Chinese medicines have been approved in the past five years
.
It is worth noting that with the continuous improvement of the R&D strength of domestic pharmaceutical companies, the era of the outbreak of innovative Chinese medicine drugs is gradually coming
.
Recently, a number of innovative Chinese medicines have been approved for marketing one after another
.
On December 16, the State Drug Administration issued a notice of drug approval to market, announcing the approval of the market registration application for Huzhen Qingfeng Capsules and Jieyu Chufan Capsules
.
Statistics show that the listing of approved Huzhen breeze capsule, man-made Yili Pharmaceutical Co.
, Ltd.
holds
.
The drug is an innovative Chinese medicine developed on the basis of clinical experience.
It has carried out a randomized, double-blind, placebo parallel controlled, multi-center clinical trial.
The clinical trial research results show that it can be used for mild to moderate acute gouty arthritis in traditional Chinese medicine.
Treatment of damp-heat accumulation syndrome
.
Jieyu Chufan Capsule is also an innovative traditional Chinese medicine developed on the basis of clinical experience.
The prescription is based on Banxia Houpu Decoction recorded in the classic TCM book "The Synopsis of the Golden Chamber" and Zhizi Houpu Decoction recorded in "Treatise on Febrile Diseases" , Carried out randomized, double-blind, positive control drugs (chemical drugs), placebo parallel controlled, multi-center clinical trials, clinical trial research results showed that it can be used for mild to moderate depression TCM syndrome differentiation is Qi stagnation, phlegm obstruction, depression and fire internal disturbance Card treatment
.
Marketing authorization holder is Shijiazhuang Yiling Pharmaceutical Co.
, Ltd
.
In addition to the above drugs, since November, four other innovative Chinese medicines have also been approved for marketing
.
Including Fangsheng Pharmaceutical’s Xuanqijian Bone Tablets, Phoenix Pharmaceutical’s Qizhi Yishen Capsules, Tasly’s Kunxinning Granules, and Kangyuan Pharmaceutical’s Class 1.
1 New Drug Yinqiao Qingre Tablets
.
Among them, Xuanqijian bone tablets can be used to treat mild to moderate knee osteoarthritis in traditional Chinese medicine, which is a syndrome of stasis of tendons and veins; Qizhi Yishen capsule can be used for the treatment of early diabetic nephropathy syndrome of Qi and Yin; Kunxinning granules are Class 1.
1 innovative Chinese medicine, once used as Kunyining granules, is indicated for female menopausal syndrome; Kangyuan Pharmaceutical's Yinqiao Qingre Tablets will provide a new treatment option for patients with exogenous wind-heat common cold
.
Industry analysts believe that the above results are in recent years.
Through continuous promotion of the reform of the review and approval mechanism of Chinese medicines, the establishment and improvement of the registration management system and technical evaluation system in line with the characteristics of Chinese medicines, and the clinical value-oriented, accelerate the promotion of the development of new Chinese medicines, and the innovation of Chinese medicines The pharmaceutical field is constantly achieving new breakthroughs
.
According to the current development trend of innovative traditional Chinese medicines, the future innovative achievements of traditional Chinese medicines are expected to continue to emerge.
By 2024, the market size of Chinese patent medicines in China is expected to reach 1,137.
5 billion yuan
.
.
Statistics show that in 2020, the State Food and Drug Administration has approved 48 innovative drugs to be marketed.
There are only 3 traditional Chinese medicines.
They are Lianhuaqing Cough Tablets from Ling Pharmaceutical, Muscle and Bone Analgesic Gel from Kangyuan Pharmaceutical, and Wuhe Boao The total alkaloid tablets of mulberry branches
.
Although the number is not large, it has been a year in which more new Chinese medicines have been approved in the past five years
.
It is worth noting that with the continuous improvement of the R&D strength of domestic pharmaceutical companies, the era of the outbreak of innovative Chinese medicine drugs is gradually coming
.
Recently, a number of innovative Chinese medicines have been approved for marketing one after another
.
On December 16, the State Drug Administration issued a notice of drug approval to market, announcing the approval of the market registration application for Huzhen Qingfeng Capsules and Jieyu Chufan Capsules
.
Statistics show that the listing of approved Huzhen breeze capsule, man-made Yili Pharmaceutical Co.
, Ltd.
holds
.
The drug is an innovative Chinese medicine developed on the basis of clinical experience.
It has carried out a randomized, double-blind, placebo parallel controlled, multi-center clinical trial.
The clinical trial research results show that it can be used for mild to moderate acute gouty arthritis in traditional Chinese medicine.
Treatment of damp-heat accumulation syndrome
.
Jieyu Chufan Capsule is also an innovative traditional Chinese medicine developed on the basis of clinical experience.
The prescription is based on Banxia Houpu Decoction recorded in the classic TCM book "The Synopsis of the Golden Chamber" and Zhizi Houpu Decoction recorded in "Treatise on Febrile Diseases" , Carried out randomized, double-blind, positive control drugs (chemical drugs), placebo parallel controlled, multi-center clinical trials, clinical trial research results showed that it can be used for mild to moderate depression TCM syndrome differentiation is Qi stagnation, phlegm obstruction, depression and fire internal disturbance Card treatment
.
Marketing authorization holder is Shijiazhuang Yiling Pharmaceutical Co.
, Ltd
.
In addition to the above drugs, since November, four other innovative Chinese medicines have also been approved for marketing
.
Including Fangsheng Pharmaceutical’s Xuanqijian Bone Tablets, Phoenix Pharmaceutical’s Qizhi Yishen Capsules, Tasly’s Kunxinning Granules, and Kangyuan Pharmaceutical’s Class 1.
1 New Drug Yinqiao Qingre Tablets
.
Among them, Xuanqijian bone tablets can be used to treat mild to moderate knee osteoarthritis in traditional Chinese medicine, which is a syndrome of stasis of tendons and veins; Qizhi Yishen capsule can be used for the treatment of early diabetic nephropathy syndrome of Qi and Yin; Kunxinning granules are Class 1.
1 innovative Chinese medicine, once used as Kunyining granules, is indicated for female menopausal syndrome; Kangyuan Pharmaceutical's Yinqiao Qingre Tablets will provide a new treatment option for patients with exogenous wind-heat common cold
.
Industry analysts believe that the above results are in recent years.
Through continuous promotion of the reform of the review and approval mechanism of Chinese medicines, the establishment and improvement of the registration management system and technical evaluation system in line with the characteristics of Chinese medicines, and the clinical value-oriented, accelerate the promotion of the development of new Chinese medicines, and the innovation of Chinese medicines The pharmaceutical field is constantly achieving new breakthroughs
.
According to the current development trend of innovative traditional Chinese medicines, the future innovative achievements of traditional Chinese medicines are expected to continue to emerge.
By 2024, the market size of Chinese patent medicines in China is expected to reach 1,137.
5 billion yuan
.
